Olema Pharmaceuticals Plummets 41% After Roche’s Breast Cancer Trial Failure
Olema Pharmaceuticals (OLMA) shares cratered 41% Monday following Roche's disappointing Phase 3 trial results for breast cancer treatment giredestrant. The persevERA study failed to demonstrate statistically significant improvement in progression-free survival, sending shockwaves through the biotech sector.
Roche shares fell as much as 7.5% - their steepest single-day decline in nearly a year. The market punished Olema despite its separate drug development program, highlighting investor sensitivity in the competitive breast cancer therapeutics space.
Analysts at Stifel suggest the sell-off may present a buying opportunity for those bullish on Olema's palazestrant, currently in Phase 3 trials with results expected by 2028. The drug represents Olema's independent pipeline in metastatic breast cancer treatment.
